Company profile: Delfi Diagnostics
1.1 - Company Overview
Company description
- Provider of high-precision, non-invasive blood tests for early cancer detection, including the FirstLook Lung test using DNA fragment patterns; leverages machine learning and fragmentomics to analyze cell-free DNA fragments; and runs the CASCADE-LUNG clinical study to validate blood-based lung cancer screening technology.
Products and services
- CASCADE-LUNG: A large-scale clinical study validating the effectiveness of a blood-based screening technology for lung cancer, focused on early detection performance
- FirstLook Lung test: A laboratory-developed, high-precision blood test that detects lung cancer early by analyzing DNA fragment patterns in blood, non-invasive and screening-focused
- Machine Learning and Fragmentomics: A computational platform that utilizes machine learning to analyze cell-free DNA fragments in blood to enable early cancer detection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Delfi Diagnostics
Microarrays
HQ: United States
Website
- Description: Provider of microarray platforms and services for analyte testing, diagnostics, and personalized medicine, including pathway-focused gene expression arrays (MI PathArray), whole-genome microarrays (MI ReadyArray), DNA and protein/antibody arrays, assay development, and lab services for RNA profiling and microarray assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Microarrays company profile →
Arivale
HQ: United States
Website
- Description: Provider of a scientific path for individuals to optimize wellness and avoid disease for a life filled with joyful moments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arivale company profile →
Celmatix
HQ: United States
Website
- Description: Provider of preclinical discovery and development focused on women’s ovarian health, including target identification and validation for endometriosis, PCOS, and ovarian senescence; collaborative discovery, development, and commercialization with Evotec and Bayer; contraceptive target discovery supported by the Bill & Melinda Gates Foundation; and proprietary cohorts, annotations, and NLP-driven research tools.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celmatix company profile →
Epic Sciences
HQ: United States
Website
- Description: Provider of real-time, blood-based cancer diagnostics and comprehensive profiling via a single blood draw, leveraging CTCs, ctDNA, and immune-cell analysis for insights into prostate and breast cancers; offers AR-V7 test for metastatic castration-resistant prostate cancer, DefineMBC for metastatic breast cancer, and biopharma solutions for biomarker verification, novel PD marker development, and clinical analysis for drug efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epic Sciences company profile →
Ethris
HQ: Germany
Website
- Description: Provider of mRNA therapeutics and LNP delivery solutions focused on respiratory diseases and vaccines. Offers the SNIM RNA platform for stabilized non-immunogenic mRNA therapies and the SNaP LNP platform for targeted, inhalable delivery. Pipeline includes ETH47, ETH42, and ETH45 for respiratory indications. Provides in-house and partnered manufacturing with HPLC-free processes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ethris company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Delfi Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Delfi Diagnostics
2.2 - Growth funds investing in similar companies to Delfi Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Delfi Diagnostics
4.2 - Public trading comparable groups for Delfi Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →